Healthcare Industry News:  Novo Nordisk 

Biopharmaceuticals Litigation

 News Release - December 14, 2006

Court Denies Novo Nordisk's Motion for Preliminary Injunction Against Exubera

NEW YORK, Dec. 14 (HSMN NewsFeed) -- Pfizer Inc said today that the U.S. District Court for the Southern District of New York has denied a motion for a preliminary injunction that would have blocked further sales of its inhalable insulin medication, ExuberaŽ, in the U.S. The preliminary injunction was requested by Novo Nordisk as part of a patent infringement case that will be heard by the same court.

Exubera is the only inhalable form of insulin to be approved by the FDA. The court's decision allows the product to remain on the U.S. market, and available to patients, while the case proceeds to trial.



Source: Pfizer

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.